Skip to content

Evaluation of Bone Metabolism Biomarkers in Periodontal Diseases

Evaluation Of Biomarkers Associated With Bone Metabolism İn Patients With Different Periodontal Status

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05702892
Enrollment
60
Registered
2023-01-27
Start date
2020-11-05
Completion date
2021-11-05
Last updated
2023-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal Diseases

Keywords

periodontitis, saliva, sclerostin

Brief summary

This study evaluates the levels of biomarkers associated with bone metabolism in patients with different periodontal conditions.

Detailed description

Background: In this study, the levels of bone metabolism markers found in the saliva of individuals with different periodontal conditions were compared and the relationship of these markers with periodontal status was examined. Method: A total of 60 individuals, 20 with periodontitis (P), 20 with gingivitis (G), and 20 with periodontal healthy (S), were included in the study. Periodontal clinical parameters (plaque index, gingival index, bleeding on probing, clinical attachment level and probing pocket depth) and saliva samples were obtained from the individuals. Bone metabolism biomarker (necrotizing factor (TNF)-α, osteoprotegerin (OPG), nuclear factor kappa-β receptor activator ligand (RANKL) and sclerostin) levels in saliva samples were evaluated by enzyme-linked immunosorbent assay (ELISA).

Interventions

DIAGNOSTIC_TESTELISA

ELISA(enzyme-linked immunosorbent assay)

Sponsors

Necmettin Erbakan University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* 18-65 years old. * not having any systemic disease that may affect periodontal status * not smoking and alcohol use * volunteer to participate in the study

Exclusion criteria

* periapical pathologies; * resulting from orthodontics and occlusion extreme forces, including mechanical forces; * chronic high-dose steroid therapy; * radiation or immunosuppressive therapy; * pregnancy; * breastfeeding; * allergy or sensitivity to any medication. * Periodontal therapy or drug therapy for at least 6 months of study participants

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of bone metabolism biomarkers in different periodontal conditionsbaselineThe levels of bone metabolism markers in the saliva of individuals with different periodontal status were compared and the relationship of these markers with periodontal status was examined.

Secondary

MeasureTime frameDescription
Probing pocket depthbaselineProbing pocket depth(PPD) was measured for determining the severity of the disease and clinical outcome. High probing depth shows more severe periodontal disease.
Gingival indexbaselineThe differences in gingival index scores between periodontally healthy and periodontitis.The gingival index was recorded for determining and classifying gingival status. The gingival index (Gİ) scores each site on a 0 being normal and 3 being severe inflammation characterized by edema, redness, swelling and spontaneous bleeding.
Plaque indexbaselineThe differences in plaque index scores between periodontally healthy and periodontitis. Plaque index (PI) was recorded for determining and classifying oral hygiene status. The plaque index (PI) scores each site on a with 0 being no plaque in gingival area and 3 abundance of soft matter within the gingival pocket and/or on the gingival margin and adjacent tooth surface.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026